IQVIA Holdings Inc. (NYSE:IQV) Short Interest Update

IQVIA Holdings Inc. (NYSE:IQV) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 2,910,000 shares, a decline of 5.8% from the September 30th total of 3,090,000 shares. Based on an average trading volume of 1,020,000 shares, the short-interest ratio is currently 2.9 days. Approximately 1.6% of the shares of the stock are short sold.

IQVIA Trading Up 0.9 %

IQV stock traded up $1.80 on Friday, reaching $207.62. The company’s stock had a trading volume of 90,541 shares, compared to its average volume of 1,079,387. The firm has a market cap of $37.85 billion, a PE ratio of 26.73, a PEG ratio of 2.11 and a beta of 1.49. The business has a fifty day simple moving average of $235.10 and a two-hundred day simple moving average of $229.89. IQVIA has a 12-month low of $181.03 and a 12-month high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently modified their holdings of IQV. Canada Pension Plan Investment Board raised its stake in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after buying an additional 211,653 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of IQVIA by 0.9% in the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after acquiring an additional 30,014 shares in the last quarter. Farallon Capital Management LLC lifted its stake in shares of IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after purchasing an additional 86,870 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of IQVIA by 3.8% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after purchasing an additional 92,293 shares in the last quarter. Finally, Capital Research Global Investors grew its stake in IQVIA by 7.2% in the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after purchasing an additional 143,533 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on IQV shares. Barclays dropped their price target on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday. Robert W. Baird lowered their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday. Finally, UBS Group raised their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $265.07.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.